BeyondSpring (BYSI) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NewcelX (NCEL) has outperformed BeyondSpring (BYSI) over the past year, losing 22.3% versus a loss of 82.8%. Over five years, BYSI leads with a -97.7% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($14.7 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BYSI | NCEL |
|---|---|---|
| Share price | $0.33 | $2.54 |
| Market cap | $13.66M | $14.67M |
| 1-day change | -24.49% | -5.58% |
| YTD return | -79.75% | +33.68% |
| 1-year return | -82.77% | -22.32% |
| 5-year return | -97.70% | -99.65% |
| P/E ratio (TTM) | — | 4.88 |
| EPS (TTM) | $-0.20 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-1.01M | $-8.30M |
| 52-week high | $2.44 | $5.12 |
| 52-week low | $0.299 | $1.83 |
| Distance from 52-week high | -86.48% | -50.39% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +805.51% |
| Average volume | 261.79K | 13.34K |
| Shares outstanding | 41.41M | 5.78M |
| Employees | 44 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed BYSI by 60.4 percentage points over the past year.
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BYSI vs NCEL FAQ
Which is bigger, BeyondSpring or NewcelX?
NewcelX (NCEL) is larger, with a market capitalization of $14.67M compared with $13.66M for BeyondSpring (BYSI).
Which stock has performed better over the past year, BYSI or NCEL?
NCEL returned -22.32% over the past 12 months, compared with -82.77% for BYSI (price return, excluding dividends). Past performance does not predict future results.
Are BeyondSpring and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.